Image: The Globe and MailModerna shares surge as melanoma vaccine with Merck succeeds in large trial - The Globe and Mail
• Moderna and Merck announced that a personalized mRNA cancer vaccine, used alongside the immunotherapy drug Keytruda, successfully reduced the risk of recurrence and spread of melanoma in a late-stage trial. • The positive interim analysis caused Moderna’s shares to surge by as much as 160 per cent on Wednesday. • This development marks a significant milestone in the emerging field of personalized cancer treatment, potentially benefiting thousands of high-risk patients who have undergone tumor removal surgery.
theglobeandmail.com
